NOV 20, 2020 7:30 AM PST

Cat Parasite Gives Clues on New Drug Targets for Schizophrenia

WRITTEN BY: Annie Lennon

Researchers from the UK and France have discussed a mechanism of action behind the infamous Toxoplasma gondii parasite transferred to humans from cat litter that may lead to the development of new treatments for schizophrenia and other neurological disorders. 

Estimates say that between 30% and 50% of the world’s population is infected with the parasite. While those infected are usually asymptomatic, it is known to cause headaches, confusion, and seizures in others. It is also linked to an increase in the risk of developing schizophrenia and behavioral changes in rodents. 

T. gondii is only able to sexually reproduce in cats. In doing so, it forms cysts that are excreted in the cat’s feces, where they can then enter new hosts via ingestion of anything contaminated by them. This includes water, soil, vegetables, blood transfusions, and mother to fetus. Virtually any warm-blooded animal may be a host.

After being infected, the infection enters a dormant phase within a few weeks, during which it forms cysts in the brain. These cysts remain there for years, where they affect neurotransmitter norepinephrine levels. 

In their new study, the researchers found that the parasite’s ability to reduce norepinephrine disrupts the body’s ability to regulate the immune system. This then leads to an overactive immune response, which may then change the host’s cognitive functions. 

“Our insight connects the two opposing theories for how Toxoplasma alters host behavior and this may apply to other infections of the nervous system,” says Glenn McConkey, one of the researchers behind the paper. “

One school believes that behavior changes are invoked by the immune response to infection and the other that changes are due to altered neurotransmitters.”

The researchers say that their findings will contribute to our understanding of the link between brain inflammation and cognition. As such, they hope that their work will go on to inform the development of antipsychotic treatments. 

 

Sources: Neuroscience NewsTrends in Immunology

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
JUL 16, 2022
Drug Discovery & Development
Whole Blood Exchange May Reduce Amyloid Plaques in Alzheimer's
JUL 16, 2022
Whole Blood Exchange May Reduce Amyloid Plaques in Alzheimer's
Whole blood exchange reduces the formation of amyloid beta plaques in mouse models of Alzheimer's disease. The corre ...
JUL 25, 2022
Cardiology
Drug that Can Help Men Live Longer?
JUL 25, 2022
Drug that Can Help Men Live Longer?
A new study from the University of Virginia School of Medicine and recently published in Science discusses how the loss ...
AUG 15, 2022
Drug Discovery & Development
Electrical Stimulation of Eyes Improves Symptoms of Alzheimer's, Depression
AUG 15, 2022
Electrical Stimulation of Eyes Improves Symptoms of Alzheimer's, Depression
Electrical stimulation of the eye's surface may alleviate depression-like symptoms and improve cognitive function in ...
AUG 25, 2022
Drug Discovery & Development
Seasonal Flu Could Get Knockout Punch from Antiviral Drugs and Antibody Therapy Combo
AUG 25, 2022
Seasonal Flu Could Get Knockout Punch from Antiviral Drugs and Antibody Therapy Combo
In a recent study published in Cell Reports Medicine, a team of researchers from McMaster University in Ontario, Canada ...
SEP 17, 2022
Drug Discovery & Development
Dental Care Linked to Better Heart Attack Outcomes
SEP 17, 2022
Dental Care Linked to Better Heart Attack Outcomes
People who receive periodontal care have shorter hospital stays following a heart attack. The corresponding study was pu ...
SEP 17, 2022
Drug Discovery & Development
Daily Multivitamin May Slow Down Cognitive Decline in Older Adults
SEP 17, 2022
Daily Multivitamin May Slow Down Cognitive Decline in Older Adults
Daily multivitamins may slow down cognitive decline among older adults. The corresponding study was published in Alzheim ...
Loading Comments...